Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)

Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.